for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Inflarx NV

IFRX.OQ

Latest Trade

2.90USD

Change

0.04(+1.40%)

Volume

88,534

Today's Range

2.80

 - 

2.90

52 Week Range

2.45

 - 

52.41

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.86
Open
2.86
Volume
88,534
3M AVG Volume
18.17
Today's High
2.90
Today's Low
2.80
52 Week High
52.41
52 Week Low
2.45
Shares Out (MIL)
25.96
Market Cap (MIL)
74.26
Forward P/E
-1.25
Dividend (Yield %)
--

Latest Developments

More

Inflarx Reports Cash And Cash Equivalents Plus Securities And Other Investments Of EUR 138.3 Million As Of June 30

InflaRx Reports Additional Analysis Of The SHINE Phase IIb Results For IFX-1 In Hidradenitis Suppurativa

Inflarx NV Files For Potential Mixed Shelf Offering; Size Not Disclosed

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Inflarx NV

Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.

Industry

Biotechnology & Drugs

Contact Info

Winzerlaer Str. 2

+49.3641.508180

http://www.inflarx.de/Home.html

Key Stats

3.25 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (EUR)

2017

-2.600

2018

-1.190

2019(E)

-2.050
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
0.51
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.75
LT Debt To Equity (MRQ)
0.49
Return on Investment (TTM)
-28.74
Return on Equity (TTM)
-27.15

Latest News

BRIEF-Inflarx Announces Pricing Of Primary And Secondary Offering Of Common Shares

* INFLARX N.V. ANNOUNCES PRICING OF PRIMARY AND SECONDARY OFFERING OF COMMON SHARES

BRIEF-Inflarx NV Files For Offering Of Up To 1.5 Mln Common Shares

* INFLARX NV FILES FOR OFFERING OF UP TO 1.5 MILLION COMMON SHARES AND SELLING SHAREHOLDERS OFFERING UP TO 1.5 MILLION COMMON SHARES - SEC FILING Source text: (https://bit.ly/2HM0lkG) Further company coverage:

BRIEF-InflaRx Full Year 2017 Financial & Operating Results

* INFLARX NV - CASH AND CASH EQUIVALENTS TOTALED EUR 123.3 MILLION AS OF DECEMBER 31, 2017 COMPARED TO EUR 29.1 MILLION AS OF DECEMBER 31, 2016 Source text for Eikon: Further company coverage:

BRIEF-Inflarx Announces First Patient Enrolled In Phase Iib Trial With Lead Candidate Ifx-1 In Hidradenitis Suppurativa

* INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE IIB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA Source text for Eikon: Further company coverage:

BRIEF-Inflarx Receives IND Acceptance To Proceed With A Phase IIB Trial With Lead Candidate IFX-1 In Hidradenitis Suppurativa

* INFLARX RECEIVES IND ACCEPTANCE TO PROCEED WITH A PHASE IIB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA

BRIEF-Ra Capital Management Reports 12.3 Pct Passive Stake In Inflarx Nv

* RA CAPITAL MANAGEMENT LLC REPORTS 12.3 PERCENT PASSIVE STAKE IN INFLARX NV AS OF NOVEMBER 8 - SEC FILING Source text: [http://bit.ly/2kmho2j] Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up